66810-01-3

Basic information

• Product Name: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL
• Synonyms: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL;2-(4-bromophenyl)-2-methylpropane-1,3-dinol
• CAS NO: 66810-01-3
• Molecular Formula: C₁₀H₁₃BrO₂
• Molecular Weight: 245.11302
• Mol File: 66810-01-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL(66810-01-3)
• EPA Substance Registry System: 2-(4-BROMOPHENYL)-2-METHYLPROPANE-1,3-DIOL(66810-01-3)

Safety Data

• Hazardous Substances Data: 66810-01-3(Hazardous Substances Data)

Usage

Class

Organic compound

Subcategory

Secondary alcohols and brominated compounds

Uses

Organic synthesis, pharmaceutical research, potential drug development, building block for complex organic compounds

Structural features

Chiral center, reactive

Reactivity

Capable of reacting in organic synthesis and pharmaceutical research

Upstream product

• 872882-98-9 diethyl 2-(4-bromophenyl)-2-methylmalonate 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 93139-85-6 2-(4-bromophenyl)malonic acid diethyl ester 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 50-00-0 formaldehyd 
• 40460-91-1 2-(4-bromophenyl)propanal 
• 80909-78-0 p-bromo-α-methylstyrene oxide 
• 99-90-1 para-bromoacetophenone 

Downstream Products

• 872882-97-8 3-(4-bromophenyl)-3-methyloxetane 
• 66810-34-2 3-(4-bromophenyl)-3-methylthietane-1,1-dioxide 
• 66810-27-3 3-(4-bromophenyl)-3-methylthietane 
• 1431616-42-0 (4-(3-methyloxetan-3-yl)phenyl)boronic acid 
• 1431616-23-7 6-(4-(3-methyloxetan-3-yl)phenyl)nicotinonitrile 
• 161636-15-3 (Z)-4-(4-bromophenyl)-1,1,1-trifluoro-4-methoxybut-3-en-2-one 

Relevant articles and documents

Chemical space exploration of oxetanes

This paper focuses on new derivatives bearing an oxetane group to extend accessible chemical space for further identification of kinase inhibitors. The ability to modulate kinase activity represents an important therapeutic strategy for the treatment of h

Enantioselective Desymmetrization of 1,3-Diols by a Chiral DMAP Derivative

We developed an enantioselective desymmetrization of 1,3-diols by a chiral N,N-dimethyl-4-aminopyridine (DMAP) derivative containing a 1,1-binaphthyl with tert-alcohol units. The reactions required only 0.1 mol% of catalyst and showed moderate to high chemoselectivity (monoacylation vs. diacylation) and enantioselectivity (14 examples, up to 95:5 er). Several control experiments revealed that diol units in both the substrate and the catalyst are important to achieve high enantioselectivity.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

SUBSTITUTED BIPIPERIDINYL DERIVATIVES

The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Metabolically stable tert-butyl replacement

Susceptibility to metabolism is a common issue with the tert-butyl group on compounds of medicinal interest. We demonstrate an approach of removing all the fully sp3 C-Hs from a tert-butyl group: replacing some C-Hs with C-Fs and increasing the s-character of the remaining C-Hs. This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability. Trifluoromethylcyclopropyl-containing analogues had consistently higher metabolic stability in vitro and in vivo compared to their tert-butyl-containing counterparts.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN

The present invention relates to novel pyridyl-lactams, compounds of the formula (I), wherein R1 is a group of the formula G1, G2, G3 or G4 depicted below, and R3, Y, R6, R7, R8, R13, a, n and m are as defined herein, their pharmaceutically acceptable salts, pharmaceutical compositions, their preparation and intermediates therefrom, and their use in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1B antagonist is indicated.